arrow_back Trending Legislation
Share share

Gwenn’s Law: Increasing Women’s Participation in Clinical Trials and Rare Disease Awareness

This bill aims to boost women's involvement in clinical trials and raise awareness about rare diseases and blood clotting disorders. It introduces public awareness campaigns, establishes a task force for rare diseases, and requires the development of an action plan.
Key points
Launch of public awareness campaigns in hospitals and clinics to encourage women to join clinical trials.
Allocation of $20 million annually (fiscal years 2027-2031) for campaigns on clinical trials and bleeding disorders in women.
Creation of a permanent Interagency Task Force to advance treatments for rare diseases.
Development of a public action plan focused on rare diseases that disproportionately impact women.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Gwenn’s Law
Print number: HR 7694
Sponsor: Rep. Gottheimer, Josh [D-NJ-5]
Process start date: 2026-02-25
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-3.1-pro-preview
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Gwenn’s Law: Increasing Women’s Participation in Clinical Trials and Rare Disease Awareness

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 7694.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2026-02-25.

What are the main provisions?

Key points include:

  • Launch of public awareness campaigns in hospitals and clinics to encourage women to join clinical trials.
  • Allocation of $20 million annually (fiscal years 2027-2031) for campaigns on clinical trials and bleeding disorders in women.
  • Creation of a permanent Interagency Task Force to advance treatments for rare diseases.
  • Development of a public action plan focused on rare diseases that disproportionately impact women.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Gottheimer, Josh [D-NJ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-04-17.

Analysis and Potential Impact of HR 7694

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health